 |
|
Treating multiple brain tumors with radiosurgery results in improved survival
October 19, 2005Treating four or more brain tumors in a single radiosurgery session resulted in improved survival compared to whole brain radiation therapy alone, according to a study the University of Pittsburgh School of Medicine presented today at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Denver.
"Cancer patients with multiple metastases to the brain face very grim prognoses and limited treatment options," said John Flickinger, M.D., senior author of the study and professor of radiation oncology at the University of Pittsburgh School of Medicine. "In the past, these patients were not considered candidates for radiosurgery. The results of our study indicate that treating four or more brain tumors with radiosurgery is safe and effective and translates into a survival benefit for patients."
Two hundred and five patients with primary malignancies that had metastasized to the brain underwent gamma knife radiosurgery for four or more tumors during one session. Gamma knife is a non-invasive, computer-driven, bloodless brain surgery that uses cobalt 60 to destroy tumors and vascular malformations and requires no surgical incisions. The average number of brain tumors for patients in the study was five, with a range from four to 18. Radiosurgery was used alone, in combination with whole brain radiation or after failure of whole brain radiation.
Radiosurgery patients with the most prognostic factors associated with survival from brain metastases (defined as class 1 according to the Radiation Therapy Oncology Group classification system for patients with brain metastases) survived an average of 18 months, compared to a reported historical average of seven months for those who received whole brain radiation alone. Patients defined as class 2 who received radiosurgery survived nine months compared to the historical average survival of four months for patients who received whole brain radiation. Patients with the least prognostic factors associated with survival (class 3) who received radiosurgery survived an average of three months compared to the historical average survival of two months for patients who received whole brain radiation. The average overall survival for patients who received radiosurgery was eight months and the average time to progression and new brain metastases was nine months.
"The study also found that the sum of the volume of all treated brain tumors was a more significant predictor of length of survival than was the total number of brain metastases, indicating that tumor volume should be used as a criterion for radiosurgery rather than number of brain metastases," added L. Dade Lunsford, M.D., Lars Leksell professor and chairman of the department of neurological surgery at the University of Pittsburgh School of Medicine.
"Typically, only patients with one to three brain metastases are considered candidates for stereotactic radiosurgery," said Ajay K. Bhatnagar, M.D., study presenter and resident, department of radiation oncology, University of Pittsburgh School of Medicine. "However, based on the results from this study, we conclude that the number of brain metastases should not necessarily preclude patients with multiple lesions from this potentially life-saving treatment option."
Also involved in the study from the University of Pittsburgh's departments of radiation oncology and neurological surgery was Douglas Kondziolka, M.D.
University of Pittsburgh Medical Center
Radiosurgery patients with the most prognostic factors associated with survival from brain metastases (defined as class 1 according to the Radiation Therapy Oncology Group classification system for patients with brain metastases) survived an average of 18 months, compared to a reported historical average of seven months for those who received whole brain radiation alone. Patients defined as class 2 who received radiosurgery survived nine months compared to the historical average survival of four months for patients who received whole brain radiation. Patients with the least prognostic factors associated with survival (class 3) who received radiosurgery survived an average of three months compared to the historical average survival of two months for patients who received whole brain radiation. The average overall survival for patients who received radiosurgery was eight months and the average time to progression and new brain metastases was nine months.
"The study also found that the sum of the volume of all treated brain tumors was a more significant predictor of length of survival than was the total number of brain metastases, indicating that tumor volume should be used as a criterion for radiosurgery rather than number of brain metastases," added L. Dade Lunsford, M.D., Lars Leksell professor and chairman of the department of neurological surgery at the University of Pittsburgh School of Medicine.
"Typically, only patients with one to three brain metastases are considered candidates for stereotactic radiosurgery," said Ajay K. Bhatnagar, M.D., study presenter and resident, department of radiation oncology, University of Pittsburgh School of Medicine. "However, based on the results from this study, we conclude that the number of brain metastases should not necessarily preclude patients with multiple lesions from this potentially life-saving treatment option."
Also involved in the study from the University of Pittsburgh's departments of radiation oncology and neurological surgery was Douglas Kondziolka, M.D.
University of Pittsburgh Medical Center
Brain Tumors Current Events and Brain Tumors News RSSPediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma.
New approach to gene therapy may shrink brain tumors, prevent their spread
Massachusetts General Hospital (MGH) researchers are investigating a new approach to gene therapy for brain tumors - delivering a cancer-fighting gene to normal brain tissue around the tumor to keep it from spreading.
Whole brain radiation increases risk of learning and memory problems in cancer patients
Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone, according to new research from The University of Texas M. D. Anderson Cancer Center.
Family history of brain tumors linked to increased risk of brain cancer
People with a family history of cancerous brain tumors appear to be at higher risk of developing the same kind of tumors compared to people with no such family history.
Barrow researchers identify a new approach to detect the early progression of brain tumors
Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center recently participated in a pilot study with the Montreal Neurological Institute that suggests a certain type of MRI scanning can detect when a patient is failing brain tumor treatment before symptoms appear.
Drugs to inhibit blood vessel growth show promise in rat model of deadly brain tumor
In a landmark study, Medical College of Wisconsin researchers in Milwaukee report that drugs used to inhibit a specific fatty acid in rat brains with glioblastoma-like tumors not only reduced new blood vessel growth and tumor size dramatically, but also prolonged survival. The study is the featured cover story of the August, 2008 Journal of Cerebral Blood Flow & Metabolism.
Childhood brain tumor traced to normal stem cells gone bad
An aggressive childhood brain tumor known as medulloblastoma originates in normal brain "stem" cells that turn malignant when acted on by a known mutant, cancer-causing oncogene, say researchers from Dana-Farber Cancer Institute and the University of California, San Francisco (UCSF).
Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors.
A viral cloaking device
Viruses achieve their definition of success when they can thrive without killing their host. Now, biologists Pamela Bjorkman and Zhiru Yang of the California Institute of Technology have uncovered how one such virus, prevalent in humans, evolved over time to hide from the immune system.
Researchers identify promising cancer drug target in prostate tumors
Scientists at Dana-Farber Cancer Institute report they have blocked the development of prostate tumors in cancer-prone mice by knocking out a molecular unit they describe as a "powerhouse" that drives runaway cell growth.
More Brain Tumors Current Events and Brain Tumors News Articles
 | Brain Tumors: Leaving the Garden of Eden--A Survival Guide to Diagnosis, Learning the Basics, Getting Organized, and Finding Your Medical Team by Paul M. Zeltzer A guidebook for the 150,000+ people/ year and families affected by brain tumors. This book will help you learn the basics about diagnosis, getting organized and finding your medical team. Included are chapters on all major types of brain tumors & metastases, glossary, medications, using the Internet to search for information, and getting a second opinion. "Brain Tumors:Leaving the Garden of... |
 | Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors.... |
 | 100 Q&A About Brain Tumors (100 Questions Series) by Virginia Stark-Vance A patient-oriented guide to dealing with brain tumors that covers basic questions such as types of tumors, risk factors and... |
| Late Effects of Treatment for Brain Tumors (Cancer Treatment and Research) Late Effects of Treatment for Brain Tumors reviews the development of the medical team's awareness of late effects of brain tumor treatment and an overview of brain tumor survivorship. It reviews the late effects by topic and by organ systems, educates, and provides guidelines for follow up and interventions for patient survivorship. Advocacy for survivors and models for the importance of... | |
 | Curveball: When Life Throws You a Brain Tumor by Liz Holzemer Life seemed idyllic for thirty-two-year-old Liz Holzemer. Wife of Major League Baseball pitcher Mark Holzemer, Liz was enjoying a successful career as a journalist when an MRI revealed a baseball-size brain tumor she soon found out was called meningioma. Told with clarity and unwavering humor, this book is an inspirational and informative account of one woman's battle for her life. It shows... |
 | Brain Tumors (Diseases and Disorders) by Arda Darakjian Clark Brain tumors, both benign and malignant, present severe challenges to patients, their families, and to the medical professionals who treat them. This book discusses symptoms and diagnosis of brain tumors, standard and experimental treatments, and the need for care and rehabilitation following treatment.... |
| That's Unacceptable: Surviving a Brain Tumor - My Personal Story by Rebecca L. Libutti | |
 | Serendipity: An Uplifting and Practical Guide for Anyone Battling a Brain Tumor by Peggy Prichard Ross Multiple strategies for coping with brain cancer treatments and the unexpected joy you can find through fighting cancer. Includes information on Brain Biopsies, Radiation, Emergency Surgery, Stereotactic radio-surgery, Chemotherapy, Nutrition, Exercise, Managing Seizures, Coping with Headaches, Visualization, and Finding... |
 | Brain Tumors: Finding the Ark. Meeting the Challenges of Treatment Choices, Side Effects, Childrens Issues, Healthcare Costs and Long Term Survival by Paul M. Zeltzer In this sequel to Brain Tumors: Leaving the Garden of Eden, Dr. Paul continues to guide you through the brain tumor minefield so you have the best chances for quality survival. Here are the key answers to questions about medications, side effects and late effects of treatment, insurance, Medicare & HMOs, clinical trials, heredity, brain tumors in children, Complementary and Alternative... |
 | Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by H. Charles Wolf |
| © 2008 BrightSurf.com |